Overview

• In a mouse study, a vaccine combining aluminum hydroxide and a saponin-based nanoparticle produced a strong immune response with just one dose.
• The formulation accumulated intact HIV antigen in lymph nodes for up to four weeks, prolonging germinal center activity.
• Single-dose administration generated two to three times more unique B cell clones than vaccines using a single adjuvant.
• The dual-adjuvant approach is compatible with many protein-based vaccines and could simplify immunization schedules for diseases such as influenza and SARS-CoV-2.
• With the SMNP adjuvant already in first-in-human trials, researchers are preparing to evaluate the combined strategy in clinical studies.